List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/265745/publications.pdf Version: 2024-02-01



DETED RDUST

#	Article	IF	CITATIONS
1	Molecular imaging of lf receptors: synthesis and evaluation of the potent $lf1$ selective radioligand [18F]fluspidine. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 540-551.	3.3	66
2	Evaluation of Spirocyclic 3-(3-Fluoropropyl)-2-benzofurans as σ ₁ Receptor Ligands for Neuroimaging with Positron Emission Tomography. Journal of Medicinal Chemistry, 2009, 52, 6062-6072.	2.9	49
3	First-in-human PET quantification study of cerebral α4β2* nicotinic acetylcholine receptors using the novel specific radioligand (Ⱂ)-[18F]Flubatine. NeuroImage, 2015, 118, 199-208.	2.1	49
4	In vivo measurement of nicotinic acetylcholine receptors with [¹⁸ F]norchloroâ€fluoroâ€homoepibatidine. Synapse, 2008, 62, 205-218.	0.6	47
5	Development of a High-Affinity PET Radioligand for Imaging Cannabinoid Subtype 2 Receptor. Journal of Medicinal Chemistry, 2016, 59, 7840-7855.	2.9	47
6	PET imaging of α7 nicotinic acetylcholine receptors: a comparative study of [18F]ASEM and [18F]DBT-10 in nonhuman primates, and further evaluation of [18F]ASEM in humans. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1042-1050.	3.3	47
7	Synthesis, pharmacological activity and structure affinity relationships of spirocyclic l̈f1 receptor ligands with a (2-fluoroethyl) residue in 3-position. Bioorganic and Medicinal Chemistry, 2011, 19, 393-405.	1.4	46
8	Development of 18F-labeled radiotracers for neuroreceptor imaging with positron emission tomography. Neuroscience Bulletin, 2014, 30, 777-811.	1.5	46
9	Synthesis and Evaluation of Novel ¹⁸ F Labeled 2-Pyridinylbenzoxazole and 2-Pyridinylbenzothiazole Derivatives as Ligands for Positron Emission Tomography (PET) Imaging of β-Amyloid Plaques. Journal of Medicinal Chemistry, 2012, 55, 9283-9296.	2.9	45
10	PET Imaging for Early Detection of Alzheimer's Disease. PET Clinics, 2017, 12, 329-350.	1.5	44
11	Molecular imaging of α7 nicotinic acetylcholine receptors: design and evaluation of the potent radioligand [18F]NS10743. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 791-800.	3.3	36
12	Synthesis of spirocyclic σ1 receptor ligands as potential PET radiotracers, structure–affinity relationships and in vitro metabolic stability. Bioorganic and Medicinal Chemistry, 2009, 17, 3630-3641.	1.4	36
13	Norchloro-fluoro-homoepibatidine: specificity to neuronal nicotinic acetylcholine receptor subtypes in vitro. Il Farmaco, 2004, 59, 785-792.	0.9	35
14	A new 18F-labeled fluoroacetylmorpholino derivative of vesamicol for neuroimaging of the vesicular acetylcholine transporter. Nuclear Medicine and Biology, 2008, 35, 185-195.	0.3	34
15	Assessment of α7 nicotinic acetylcholine receptor availability in juvenile pig brain with [18F]NS10743. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1541-1549.	3.3	34
16	Evaluation of the Enantiomer Specific Biokinetics and Radiation Doses of [18F]Fluspidineâ \in "A New Tracer in Clinical Translation for Imaging of If 1 Receptors. Molecules, 2016, 21, 1164.	1.7	34
17	A novel thermoregulatory role for <scp>PDE</scp> 10A in mouse and human adipocytes. EMBO Molecular Medicine, 2016, 8, 796-812.	3.3	34
18	Positron emission tomography imaging of the serotonin transporter in the pig brain using [11C](+)-McN5652 and S-([18F]fluoromethyl)-(+)-McN5652. Synapse, 2003, 47, 143-151.	0.6	32

#	Article	IF	CITATIONS
19	Cannabinoid receptor type 2 (CB2)-selective N-aryl-oxadiazolyl-propionamides: synthesis, radiolabelling, molecular modelling and biological evaluation. Organic and Medicinal Chemistry Letters, 2012, 2, 32.	2.0	32
20	Radiosynthesis and first evaluation in mice of [18F]NS14490 for molecular imaging of α7 nicotinic acetylcholine receptors. Bioorganic and Medicinal Chemistry, 2013, 21, 2635-2642.	1.4	31
21	Synthesis, Characterization, and Metabolism Studies of Fluspidine Enantiomers. ChemMedChem, 2013, 8, 2047-2056.	1.6	29
22	Synthesis and biological evaluation of both enantiomers of [18F]flubatine, promising radiotracers with fast kinetics for the imaging of α4β2-nicotinic acetylcholine receptors. Bioorganic and Medicinal Chemistry, 2014, 22, 804-812.	1.4	29
23	^{99m} Tc-labeled benzothiazole and stilbene derivatives as imaging agents for Aβ plaques in cerebral amyloid angiopathy. MedChemComm, 2014, 5, 153-158.	3.5	28
24	Sigma-1 and dopamine D2/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [18F] fluspidine and [18F] fallypride PET study. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1103-1115.	3.3	28
25	Distinctive In Vivo Kinetics of the New Ïf ₁ Receptor Ligands (<i>R</i>)-(+)- and (<i>S</i>)-(–)- ¹⁸ F-Fluspidine in Porcine Brain. Journal of Nuclear Medicine, 2014, 55, 1730-1736.	2.8	26
26	¹⁸ F-Labeled 1,4-Dioxa-8-azaspiro[4.5]decane Derivative: Synthesis and Biological Evaluation of a If ₁ Receptor Radioligand with Low Lipophilicity as Potent Tumor Imaging Agent. Journal of Medicinal Chemistry, 2015, 58, 5395-5407.	2.9	26
27	Development of Radioligands for the Imaging of ?7 Nicotinic Acetylcholine Receptors with Positron Emission Tomography. Current Drug Targets, 2012, 13, 594-601.	1.0	26
28	Radiosynthesis of racemic and enantiomerically pure (â^')-[18F]flubatine—A promising PET radiotracer for neuroimaging of α4β2 nicotinic acetylcholine receptors. Applied Radiation and Isotopes, 2013, 74, 128-136.	0.7	25
29	PET Imaging Evaluation of Four Ïf < sub>1 Radiotracers in Nonhuman Primates. Journal of Nuclear Medicine, 2017, 58, 982-988.	2.8	24
30	1-(4-[¹⁸ F]Fluorobenzyl)-4-[(tetrahydrofuran-2-yl)methyl]piperazine: A Novel Suitable Radioligand with Low Lipophilicity for Imaging σ ₁ Receptors in the Brain. Journal of Medicinal Chemistry, 2017, 60, 4161-4172.	2.9	24
31	Imaging sigma receptors in the brain: New opportunities for diagnosis of Alzheimer's disease and therapeutic development. Neuroscience Letters, 2019, 691, 3-10.	1.0	24
32	Radiofluorination and biological evaluation of N-aryl-oxadiazolyl-propionamides as potential radioligands for PET imaging of cannabinoid CB2 receptors. Organic and Medicinal Chemistry Letters, 2013, 3, 11.	2.0	22
33	Novel Radioligands for Cyclic Nucleotide Phosphodiesterase Imaging with Positron Emission Tomography: An Update on Developments Since 2012. Molecules, 2016, 21, 650.	1.7	21
34	Novel 99mTc labeled σ receptor ligand as a potential tumor imaging agent. Science in China Series B: Chemistry, 2006, 49, 169-176.	0.8	20
35	Fully automated radiosynthesis of both enantiomers of [18F]Flubatine under GMP conditions for human application. Applied Radiation and Isotopes, 2013, 80, 7-11.	0.7	20
36	PET imaging evaluation of [18F]DBT-10, a novel radioligand specific to α7 nicotinic acetylcholine receptors, in nonhuman primates. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 537-547.	3.3	20

#	Article	IF	CITATIONS
37	Evaluation of metabolism, plasma protein binding and other biological parameters after administration of (â^')-[18F]Flubatine in humans. Nuclear Medicine and Biology, 2014, 41, 489-494.	0.3	18
38	Synthesis and inÂvitro evaluation of new fluorinated quinoline derivatives with high affinity for PDE5: Towards the development of new PET neuroimaging probes. European Journal of Medicinal Chemistry, 2017, 136, 548-560.	2.6	18
39	18 F-Labeled indole-based analogs as highly selective radioligands for imaging sigma-2 receptors in the brain. Bioorganic and Medicinal Chemistry, 2017, 25, 3792-3802.	1.4	18
40	Improved in vivo PET imaging of the adenosine A2A receptor in the brain using [18F]FLUDA, a deuterated radiotracer with high metabolic stability. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2727-2736.	3.3	18
41	Internal Dose Assessment of (–)- ¹⁸ F-Flubatine, Comparing Animal Model Datasets of Mice and Piglets with First-in-Human Results. Journal of Nuclear Medicine, 2014, 55, 1885-1892.	2.8	17
42	Automation of the radiosynthesis and purification procedures for [18F]Fluspidine preparation, a new radiotracer for clinical investigations in PET imaging of $If1$ receptors in brain. Applied Radiation and Isotopes, 2014, 84, 1-7.	0.7	17
43	Synthesis and evaluation of a 18F-labeled spirocyclic piperidine derivative as promising $ f $ receptor imaging agent. Bioorganic and Medicinal Chemistry, 2014, 22, 5270-5278.	1.4	17
44	Synthesis, 18F-Radiolabelling and Biological Characterization of Novel Fluoroalkylated Triazine Derivatives for in Vivo Imaging of Phosphodiesterase 2A in Brain via Positron Emission Tomography. Molecules, 2015, 20, 9591-9615.	1.7	17
45	Radiation dosimetry of the α4β2 nicotinic receptor ligand (+)-[18F]flubatine, comparing preclinical PET/MRI and PET/CT to first-in-human PET/CT results. EJNMMI Physics, 2016, 3, 25.	1.3	17
46	Development of a Novel Nonpeptidic ¹⁸ F-Labeled Radiotracer for in Vivo Imaging of Oxytocin Receptors with Positron Emission Tomography. Journal of Medicinal Chemistry, 2016, 59, 1800-1817.	2.9	17
47	Radiosynthesis and in vivo evaluation of a fluorine-18 labeled pyrazine based radioligand for PET imaging of the adenosine A2B receptor. Bioorganic and Medicinal Chemistry, 2018, 26, 4650-4663.	1.4	17
48	Radiosynthesis and Radiotracer Properties of a 7-(2-[18F]Fluoroethoxy)-6-methoxypyrrolidinylquinazoline for Imaging of Phosphodiesterase 10A with PET. Pharmaceuticals, 2012, 5, 169-188.	1.7	16
49	Development of a New Radiofluorinated Quinoline Analog for PET Imaging of Phosphodiesterase 5 (PDE5) in Brain. Pharmaceuticals, 2016, 9, 22.	1.7	15
50	Radiosynthesis and biological evaluation of the new PDE10A radioligand [¹⁸ F]AQ28A. Journal of Labelled Compounds and Radiopharmaceuticals, 2017, 60, 36-48.	0.5	15
51	Targeting cyclic nucleotide phosphodiesterase 5 (PDE5) in brain: Toward the development of a PET radioligand labeled with fluorine-18. Bioorganic Chemistry, 2019, 86, 346-362.	2.0	14
52	Fluorineâ€Containing 6,7â€Ðialkoxybiarylâ€Based Inhibitors for Phosphodiesteraseâ€10 A: Synthesis and ir vitro Evaluation of Inhibitory Potency, Selectivity, and Metabolism. ChemMedChem, 2014, 9, 1476-1487.	¹ 1.6	13
53	A Promising PET Tracer for Imaging of α7 Nicotinic Acetylcholine Receptors in the Brain: Design, Synthesis, and in Vivo Evaluation of a Dibenzothiophene-Based Radioligand. Molecules, 2015, 20, 18387-18421.	1.7	13
54	Development of highly potent phosphodiesterase 10A (PDE10A) inhibitors: Synthesis and inÂvitro evaluation of 1,8-dipyridinyl- and 1-pyridinyl-substituted imidazo[1,5-a]quinoxalines. European Journal of Medicinal Chemistry, 2016, 107, 97-108.	2.6	13

#	Article	IF	CITATIONS
55	LC-MS Supported Studies on the in Vitro Metabolism of both Enantiomers of Flubatine and the in Vivo Metabolism of (+)-[18F]Flubatine—A Positron Emission Tomography Radioligand for Imaging α4β2 Nicotinic Acetylcholine Receptors. Molecules, 2016, 21, 1200.	1.7	12
56	Comparison of inâ€Silico, Electrochemical, inâ€Vitro and inâ€Vivo Metabolism of a Homologous Series of (Radio)fluorinated Ïf ₁ Receptor Ligands Designed for Positron Emission Tomography. ChemMedChem, 2016, 11, 2445-2458.	1.6	12
57	Studies towards the development of a PET radiotracer for imaging of the P2Y1 receptors in the brain: synthesis, 18F-labeling and preliminary biological evaluation. European Journal of Medicinal Chemistry, 2019, 165, 142-159.	2.6	12
58	PET Imaging of the Adenosine A2A Receptor in the Rotenone-Based Mouse Model of Parkinson's Disease with [18F]FESCH Synthesized by a Simplified Two-Step One-Pot Radiolabeling Strategy. Molecules, 2020, 25, 1633.	1.7	12
59	A high-yield automated radiosynthesis of the alpha-7 nicotinic receptor radioligand [18F]NS10743. Applied Radiation and Isotopes, 2015, 95, 76-84.	0.7	10
60	Varying Chirality Across Nicotinic Acetylcholine Receptor Subtypes: Selective Binding of Quinuclidine Triazole Compounds. ACS Medicinal Chemistry Letters, 2016, 7, 890-895.	1.3	10
61	Development of Highly Affine and Selective Fluorinated Cannabinoid Type 2 Receptor Ligands. ACS Medicinal Chemistry Letters, 2017, 8, 566-571.	1.3	10
62	Development of Fluorinated Non-Peptidic Ghrelin Receptor Ligands for Potential Use in Molecular Imaging. International Journal of Molecular Sciences, 2017, 18, 768.	1.8	10
63	Positron Emission Tomography Imaging Evaluation of a Novel 18F-Labeled Sigma-1 Receptor Radioligand in Cynomolgus Monkeys. ACS Chemical Neuroscience, 2020, 11, 1673-1681.	1.7	10
64	(+)-[18F]Flubatine as a novel α4β2 nicotinic acetylcholine receptor PET ligand—results of the first-in-human brain imaging application in patients with β-amyloid PET-confirmed Alzheimer's disease and healthy controls. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 731-746.	3.3	10
65	Synthesis and Biological Evaluation of a Novel 18F-Labeled Radiotracer for PET Imaging of the Adenosine A2A Receptor. International Journal of Molecular Sciences, 2021, 22, 1182.	1.8	10
66	Structure-Based Design, Optimization, and Development of [¹⁸ F]LU13: A Novel Radioligand for Cannabinoid Receptor Type 2 Imaging in the Brain with PET. Journal of Medicinal Chemistry, 2022, 65, 9034-9049.	2.9	10
67	Novel 18F-labeled dibenzylideneacetone derivatives as potential positron emission tomography probes for inÂvivo imaging of β-amyloid plaques. European Journal of Medicinal Chemistry, 2014, 84, 628-638.	2.6	9
68	Convenient recycling and reuse of bombarded [18 O]H 2 O for the production and the application of [18 F]F â^'. Applied Radiation and Isotopes, 2015, 101, 44-52.	0.7	9
69	Do spiroindolines have the potential to replace vesamicol as lead compound for the development of radioligands targeting the vesicular acetylcholine transporter?. Bioorganic and Medicinal Chemistry, 2017, 25, 5107-5113.	1.4	9
70	Synthesis, Receptor Affinity, and Antiallodynic Activity of Spirocyclic σ Receptor Ligands with Exocyclic Amino Moiety. Journal of Medicinal Chemistry, 2018, 61, 9666-9690.	2.9	9
71	Investigation of an 18F-labelled Imidazopyridotriazine for Molecular Imaging of Cyclic Nucleotide Phosphodiesterase 2A. Molecules, 2018, 23, 556.	1.7	9
72	Bridging from Brain to Tumor Imaging: (S)-(â^')- and (R)-(+)-[18F]Fluspidine for Investigation of Sigma-1 Receptors in Tumor-Bearing Mice. Molecules, 2018, 23, 702.	1.7	9

#	Article	IF	CITATIONS
73	Exploring the Metabolism of (+)-[18F]Flubatine In Vitro and In Vivo: LC-MS/MS Aided Identification of Radiometabolites in a Clinical PET Study â€. Molecules, 2018, 23, 464.	1.7	9
74	In vitro and in vivo Human Metabolism of (S)-[18F]Fluspidine – A Radioligand for Imaging σ1 Receptors With Positron Emission Tomography (PET). Frontiers in Pharmacology, 2019, 10, 534.	1.6	9
75	Synthesis and In Vitro Evaluation of 8-Pyridinyl-Substituted Benzo[e]imidazo[2,1-c][1,2,4]triazines as Phosphodiesterase 2A Inhibitors. Molecules, 2019, 24, 2791.	1.7	9
76	Pathophysiological Changes in the Enteric Nervous System of Rotenone-Exposed Mice as Early Radiological Markers for Parkinson's Disease. Frontiers in Neurology, 2021, 12, 642604.	1.1	8
77	Development of [18F]LU14 for PET Imaging of Cannabinoid Receptor Type 2 in the Brain. International Journal of Molecular Sciences, 2021, 22, 8051.	1.8	8
78	The evaluations of 99m Tc cyclopentadienyl tricarbonyl triphenyl phosphonium cation for multidrug resistance. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 3551-3554.	1.0	7
79	Synthesis and radiofluorination of novel fluoren-9-one based derivatives for the imaging of α7 nicotinic acetylcholine receptor with PET. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 1471-1475.	1.0	7
80	In vitro and in vivo evaluation of fluorinated indanone derivatives as potential positron emission tomography agents for the imaging of monoamine oxidase B in the brain. Bioorganic and Medicinal Chemistry Letters, 2021, 48, 128254.	1.0	7
81	Radiosynthesis of (S)-[18 F] T1 : The first PET radioligand for molecular imaging of α3β4 nicotinic acetylcholine receptors. Applied Radiation and Isotopes, 2017, 124, 106-113.	0.7	6
82	Development and radiosynthesis of the first ¹⁸ Fâ€labeled inhibitor of monocarboxylate transporters (MCTs). Journal of Labelled Compounds and Radiopharmaceuticals, 2019, 62, 411-424.	0.5	6
83	Design, Radiosynthesis and Preliminary Biological Evaluation in Mice of a Brain-Penetrant 18F-Labelled Ïf2 Receptor Ligand. International Journal of Molecular Sciences, 2021, 22, 5447.	1.8	6
84	Discovery and development of brain-penetrant 18F-labeled radioligands for neuroimaging of the sigma-2 receptors. Acta Pharmaceutica Sinica B, 2022, 12, 1406-1415.	5.7	6
85	Synthesis and evaluation of new 1-oxa-8-azaspiro[4.5]decane derivatives as candidate radioligands for sigma-1 receptors. Bioorganic and Medicinal Chemistry, 2020, 28, 115560.	1.4	6
86	Amphiphilic Anionic Oligomer-Stabilized Calcium Phosphate Nanoparticles with Prospects in siRNA Delivery via Convection-Enhanced Delivery. Pharmaceutics, 2022, 14, 326.	2.0	6
87	Synthesis and characterization of the two enantiomers of a chiral sigma-1 receptor radioligand: (S)-(+)- and (R)-(-)-[18F]FBFP. Chinese Chemical Letters, 2022, 33, 3543-3548.	4.8	6
88	Synthesis and biodistribution of novel ^{99m} Tcâ€nitrido methylpiperidine dithioformate derivatives as potential brain imaging agents. Journal of Labelled Compounds and Radiopharmaceuticals, 2009, 52, 183-188.	0.5	5
89	A fluoro versus a nitro derivative—a high-performance liquid chromatography study of two basic analytes with different reversed phases and silica phases as basis for the separation of a positron emission tomography radiotracer. Journal of Chromatography A, 2013, 1311, 98-105.	1.8	5
90	One-step radiosynthesis of the MCTs imaging agent [18F]FACH by aliphatic 18F-labelling of a methylsulfonate precursor containing an unprotected carboxylic acid group. Scientific Reports, 2019, 9, 18890.	1.6	5

#	Article	IF	CITATIONS
91	Radiosynthesis and Biological Investigation of a Novel Fluorine-18 Labeled Benzoimidazotriazine- Based Radioligand for the Imaging of Phosphodiesterase 2A with Positron Emission Tomography. Molecules, 2019, 24, 4149.	1.7	5
92	In Silico Finding of Key Interaction Mediated α3β4 and α7 Nicotinic Acetylcholine Receptor Ligand Selectivity of Quinuclidine-Triazole Chemotype. International Journal of Molecular Sciences, 2020, 21, 6189.	1.8	5
93	Sigma-1 Receptor Positron Emission Tomography: A New Molecular Imaging Approach Using (S)-(â~')-[18F]Fluspidine in Glioblastoma. Molecules, 2020, 25, 2170.	1.7	5
94	Development of 18F-Labeled Radiotracers for PET Imaging of the Adenosine A2A Receptor: Synthesis, Radiolabeling and Preliminary Biological Evaluation. International Journal of Molecular Sciences, 2021, 22, 2285.	1.8	5
95	Gender differences in cerebral metabolism for color processing in mice: A PET/MRI Study. PLoS ONE, 2017, 12, e0179919.	1.1	4
96	Newly Synthesized Fluorinated Cinnamylpiperazines Possessing Low In Vitro MAO-B Binding. Molecules, 2020, 25, 4941.	1.7	4
97	Development of Novel Analogs of the Monocarboxylate Transporter Ligand FACH and Biological Validation of One Potential Radiotracer for Positron Emission Tomography (PET) Imaging. Molecules, 2020, 25, 2309.	1.7	4
98	Challenges on Cyclic Nucleotide Phosphodiesterases Imaging with Positron Emission Tomography: Novel Radioligands and (Pre-)Clinical Insights since 2016. International Journal of Molecular Sciences, 2021, 22, 3832.	1.8	4
99	Synthesis and Preliminary Biological Evaluation of Indol-3-yl-oxoacetamides as Potent Cannabinoid Receptor Type 2 Ligands. Molecules, 2017, 22, 77.	1.7	3
100	Preclinical Incorporation Dosimetry of [18F]FACH—A Novel 18F-Labeled MCT1/MCT4 Lactate Transporter Inhibitor for Imaging Cancer Metabolism with PET. Molecules, 2020, 25, 2024.	1.7	3
101	Development of a Radiofluorinated Adenosine A2B Receptor Antagonist as Potential Ligand for PET Imaging. International Journal of Molecular Sciences, 2020, 21, 3197.	1.8	3
102	Validation of an LC-MS/MS Method to Quantify the New TRPC6 Inhibitor SH045 (Larixyl) Tj ETQq0 0 0 rgBT /Ove Pharmaceuticals, 2021, 14, 259.	rlock 10 T 1.7	f 50 307 Td (3
103	Quantitation of the A2A Adenosine Receptor Density in the Striatum of Mice and Pigs with [18F]FLUDA by Positron Emission Tomography. Pharmaceuticals, 2022, 15, 516.	1.7	3
104	¹⁸ F‣abeled benzylpiperazine derivatives as highly selective ligands for imaging σ ₁ receptor with positron emission tomography. Journal of Labelled Compounds and Radiopharmaceuticals, 2019, 62, 425-437.	0.5	2
105	Fourier Analysis of Cerebral Metabolism of Glucose: Gender Differences in Mechanisms of Color Processing in the Ventral and Dorsal Streams in Mice. Forecasting, 2018, 1, 135-156.	1.6	1
106	Structure–Affinity Relationships of Fluorinated Spirocyclic σ 2 Receptor Ligands with an Exocyclic Benzylamino Moiety. ChemMedChem, 2019, 14, 1392-1402.	1.6	1
107	Synthesis of Novel Fluorinated Xanthine Derivatives with High Adenosine A2B Receptor Binding Affinity. Pharmaceuticals, 2021, 14, 485.	1.7	1
108	Non-Invasive Assessment of Locally Overexpressed Human Adenosine 2A Receptors in the Heart of Transgenic Mice. International Journal of Molecular Sciences, 2022, 23, 1025.	1.8	1

#	Article	IF	CITATIONS
109	Automated radiosynthesis of the adenosine A _{2A} receptorâ€targeting radiotracer [¹⁸ F]FLUDA. Journal of Labelled Compounds and Radiopharmaceuticals, 2022, , .	0.5	1
110	Solvation effects on brain uptakes of isomers of 99m Tc brain imaging agents. Science Bulletin, 2002, 47, 1786-1791.	4.3	0
111	Carbon-11 labeled stilbene derivatives from natural products for the imaging of A <i>β</i> plaques in the brain. Radiochimica Acta, 2014, 102, 185-192.	0.5	0
112	Application of Fourier Analysis of Cerebral Glucose Metabolism in Color-Induced Long-Term Potentiation: A Novel Functional PET Spectroscopy (fPETS) Study in Mice. , 2019, , .		0
113	The sigma-1 receptor: Potential role in the modulation of cellular radiation sensitivity. Journal of Cellular Biotechnology, 2020, , 1-9.	0.1	0
114	Preclinical Evaluation of [18F]FACH in Healthy Mice and Piglets: An 18F-Labeled Ligand for Imaging of Monocarboxylate Transporters with PET. International Journal of Molecular Sciences, 2021, 22, 1645.	1.8	0
115	PET Imaging of the α4β2* Nicotinic Acetylcholine Receptors in Alzheimer's Disease. , 2021, , 345-365.		0
116	Development and Biological Evaluation of the First Highly Potent and Specific Benzamide-Based Radiotracer [18F]BA3 for Imaging of Histone Deacetylases 1 and 2 in Brain. Pharmaceuticals, 2022, 15, 324.	1.7	0

8